<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280552</url>
  </required_header>
  <id_info>
    <org_study_id>ICT-107-201</org_study_id>
    <nct_id>NCT01280552</nct_id>
  </id_info>
  <brief_title>A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoCellular Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoCellular Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in
      treating a type of brain tumor called Glioblastoma Multiforme (GBM). ICT-107 is an
      immunotherapy in which the patient's immune response will be stimulated to kill the tumor
      cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of
      the patient's white blood cells (WBC) will be removed and cultured in a laboratory with
      purified antigens, similar to those on GBM cells. The patient's own WBC/DC that have been
      exposed to the tumor antigens will then be given back to the patient as a vaccine over
      several months. The goal is for the ICT-107 vaccine to stimulate the patient's immune
      response to kill the remaining GBM tumor cells after surgery and chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed phase 2 study is a randomized, double blind, controlled study of the safety and
      efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme (GBM) following
      resection and chemoradiation. The phase 1 clinical trial demonstrated safety and promising
      efficacy in a small, open-label study. The purpose of this study is to provide information
      from a larger, controlled clinical trial. Patients must be newly diagnosed with GBM and not
      yet received chemoradiation. Patients will have had tumor resection, magnetic resonance
      imaging (MRI) and tumor assessment prior to enrollment into the study. Post surgical
      treatment consists of 6 weeks of chemotherapy (TMZ) and radiation followed by a washout
      period. After Screening and informed consent, patients will undergo apheresis at the study
      site for collection of peripheral blood mononuclear cells (PBMCs). Apheresis product will be
      sent to a central site where monocytes will be purified and cultured into dendritic cells
      (DC). DC will be pulsed with synthetic peptides that correspond to immunogenic epitopes of
      tumor antigens. The pulsed dendritic cells will then be aliquoted and frozen before shipping
      back to the site. Patients will have the autologous DCs reinfused intradermally. A control
      group will receive unpulsed autologous DC. Patients will be randomized by age in a 2:1 ratio
      to ICT-107 or control.Patients will receive at least four intradermal injections of the
      ICT-107 vaccine and additional vaccine during a maintenance phase. The primary objective is
      to compare overall survival (OS) and progression free survival (PFS) in patients when treated
      with ICT-107 versus Control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 -3 years</time_frame>
    <description>The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival in HLA-A2 Patients</measure>
    <time_frame>2-3 years</time_frame>
    <description>Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2-3 years</time_frame>
    <description>Secondary Endpoints
PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed.
Population is all randomized patients ITT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in HLA- A2 Patients</measure>
    <time_frame>2-3 yers</time_frame>
    <description>Progression Free Survival in a prespecified subpopulation of patients with HLA-A2 haplotype.
Intent to treat population includes all randomized patients. PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>ICT-107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Autologous dendritic cells that have not been pulsed with antigens</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ICT-107</intervention_name>
    <description>Autologous dendritic cells pulsed with immunogenic antigens</description>
    <arm_group_label>ICT-107</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo DC</intervention_name>
    <description>Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed, initial diagnosis of GBM. Patients must be newly diagnosed with GBM and not
             yet received chemoradiation.

          2. ≥ 18 years of age

          3. HLA-A1 or HLA-A2 positive

          4. KPS score of ≥ 70%

          5. Baseline hematologic studies and chemistry profiles must meet the following criteria:

             Hemoglobin (Hgb) &gt; 9.9 g/dL total granulocyte count &gt; than 1000/mm3 platelet count &gt;
             100,000/mm3 blood urea nitrogen (BUN) &lt; 30 mg/dL creatinine &lt; 2 mg/dL alkaline
             phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
             &lt; 4x upper limit of normal (ULN) prothrombin time (PT) and activated partial
             thromboplastin time (PTT) ≤ 1.6x control unless therapeutically warranted

          6. Female patients of child-bearing potential must have negative serum pregnancy test

          7. If not surgically sterile, male and female patients of childbearing age must use
             double barrier contraception (hormonal; intrauterine device; barrier)

          8. Sufficient paraffin embedded tumor sample for analysis MGMT methylation status

          9. Written informed consent, Release of Medical Records Form and Health Insurance
             Portability and Accountability Act (HIPAA) reviewed and signed by patient or legally
             authorized representatives

        Exclusion Criteria:

          1. Recurrent disease

          2. Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife
             and placement of Gliadel wafer

          3. Presence of any other active malignancy or prior history of malignancy (except for
             basal cell carcinoma of the skin)

          4. Severe pulmonary, cardiac or other systemic disease

          5. Congestive heart failure Class III or IV according to New York Heart Association
             (NYHA)

          6. Presence of an acute infection requiring active treatment with antibiotics/antivirals;
             prophylactic administration is allowed

          7. Known history of an autoimmune disorder

          8. Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency
             syndrome (AIDS) related illness or other serious medical illness

          9. Breastfeeding

         10. Received any other therapeutic investigational agent within 30 days of enrollment

         11. Reduction of steroids (dexamethasone) to a maximum of 2 mg twice a day (BID) prior to
             the first administration of study vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Gringeri, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoCellular Therapeutics, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birbingham School of Medicine</name>
      <address>
        <city>South Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetss General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Neuroscience Institute</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Long Island Brain Tumor Center at Neurological Surgery, PC</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sammons Cancer Center (Baylor)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.imuc.com/</url>
    <description>ImmunoCellular Therapeutics website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <results_first_submitted>October 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2014</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ICT-107</title>
          <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75">Survival is still being assessed</participants>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ICT-107</title>
          <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis</description>
        <time_frame>2 -3 years</time_frame>
        <population>Intent to treat include all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>ICT-107</title>
            <description>Treatment with autologous dendritic cells pulsed with immunogenic peptides</description>
          </group>
          <group group_id="O2">
            <title>Control Dendritic Cells</title>
            <description>Treatment with autologous dendritic cells not pulsed with immunogenic peptides</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis</description>
          <population>Intent to treat include all randomized patients</population>
          <units>months of survival</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="14.9" upper_limit="21.2"/>
                    <measurement group_id="O2" value="16.7" lower_limit="12.3" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS</title>
        <description>Secondary Endpoints
PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed.
Population is all randomized patients ITT.</description>
        <time_frame>2-3 years</time_frame>
        <population>Intent to treat includes all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>ICT-107</title>
            <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
          </group>
        </group_list>
        <measure>
          <title>PFS</title>
          <description>Secondary Endpoints
PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed.
Population is all randomized patients ITT.</description>
          <population>Intent to treat includes all randomized patients</population>
          <units>months of progression free survival</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="8.2" upper_limit="13.0"/>
                    <measurement group_id="O2" value="9.0" lower_limit="5.5" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified log rank p value stratified for age and MGMT methylation status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Stratified for age and MGMT methylation status</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival in HLA-A2 Patients</title>
        <description>Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis.</description>
        <time_frame>2-3 years</time_frame>
        <population>Patients with HLA-A2 haplotype</population>
        <group_list>
          <group group_id="O1">
            <title>ICT-107</title>
            <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in HLA-A2 Patients</title>
          <description>Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis.</description>
          <population>Patients with HLA-A2 haplotype</population>
          <units>months of survival</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="13.2" upper_limit="21.1"/>
                    <measurement group_id="O2" value="12.9" lower_limit="10.2" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival in HLA- A2 Patients</title>
        <description>Progression Free Survival in a prespecified subpopulation of patients with HLA-A2 haplotype.
Intent to treat population includes all randomized patients. PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed</description>
        <time_frame>2-3 yers</time_frame>
        <population>HLA-A2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>ICT-107</title>
            <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival in HLA- A2 Patients</title>
          <description>Progression Free Survival in a prespecified subpopulation of patients with HLA-A2 haplotype.
Intent to treat population includes all randomized patients. PFS is defined as the time from randomization until the date of documented progressive disease (PD) or death, whichever occurs first, or last date known alive and progression free if progression or death is not observed</description>
          <population>HLA-A2 patients</population>
          <units>months of progression free survival</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="6.5" upper_limit="14.0"/>
                    <measurement group_id="O2" value="7.2" lower_limit="4.6" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>Analyses were stratified for age and MGMT methylation status.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Safety population was defined as those receiving at least one dose. This included 80 patients for ICT-107 and 43 patients in the Control group.</desc>
      <group_list>
        <group group_id="E1">
          <title>ICT-107</title>
          <description>Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
ICT-107: Autologous dendritic cells pulsed with immunogenic antigens</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Autologous dendritic cells that have not been pulsed with antigens
Placebo DC: Autologous dendritic cells (DC) that have not been pulsed with antigens</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>cerebral edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>increased intracranial pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>white blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>partial seizure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony Gringeri, Ph.D. Senior Vice President Strategic Resources</name_or_title>
      <organization>ImmunoCellular Therapeutics Ltd.</organization>
      <phone>818 264 2300</phone>
      <email>anthony.gringeri@imuc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

